Press Releases Zai Lab Limited

Equities

ZLAB

US98887Q1040

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
15.91 ^USD	+1.08%		+13.08%	-41.79%

Apr. 17	Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading	MT
Apr. 11	Zai Lab CEO, Others 'Do Not Anticipate' Selling Company Shares in Remainder of 2024	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Zai Lab to Announce First Quarter 2024 Financial Results and Recent Corporate Updates on May 8, 2024	Apr. 15	BU
Zai Lab Statement on Executive Management Team's Agreement on Share Activities	Apr. 12	AQ
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities	Apr. 11	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI Meets Primary Endpoint	Apr. 02	AQ
Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs	Apr. 02	BU
Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic...	Apr. 01	BU
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases	Mar. 28	AQ
Zai Lab Partner Novocure Announces METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer	Mar. 27	BU
Zai Lab to Present Data Highlighting ZL-1310, a Novel Antibody-Drug Conjugate (ADC) for Treatment of Solid Tumors	Mar. 13	BU
Zai Lab to Present Final Overall Survival (OS) Data from Phase 3 NORA Study of ZEJULA (niraparib) in Platinum-Sensitive Recurrent Ovarian Cancer (PSROC)	Mar. 06	BU
Zai Lab Announces Participation in March Investor Conference	Mar. 06	BU
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates	Feb. 27	BU
Zai Lab to Announce Full-Year 2023 Financial Results and Recent Corporate Updates on February 27, 2024	Jan. 25	BU
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC	Jan. 10	BU
Zai Lab Announces Participation in January Investor Conference	Dec. 19	BU
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List	Dec. 13	AQ
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List	Dec. 12	BU
Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates	Nov. 07	GL
Zai Lab Announces Participation in November Investor Conferences	23-10-26	GL
Zai Lab to Announce Third Quarter 2023 Financial Results and Recent Corporate Updates on November 7, 2023	23-10-18	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Zai Lab Limited

Equities

ZLAB

US98887Q1040

Press Releases

Filters